ATF3 and non-small cell lung carcinoma: Another study suggested that α-Hederin reversed cisplatin resistance in NSCLC by silencing SLC7A11 and inhibiting miR-96-5p, activating DDIT3/ATF3-mediated ferroptosis [86].